clinical

NexGen Health in San Jose has launched a physician-led Cerebrolysin IV Therapy Program, offering advanced neurological support through a personalized 10-treatment protocol. Designed to aid patients with stroke, traumatic brain injury, cognitive decline, and neurodegenerative diseases,...

(NASDAQ:IINN) RA'ANANA, Israel, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," “Inspira Technologies,” or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced pivotal results for its HYLA blood sensor, achieving 97.35% accuracy in its latest performance testing phase that will support its upcoming U.S. Food and Drug Administration (“FDA”) submission. These results represent a significant advancement from the initial data obtained in a clinical study, as announced on March 4, 2025.

WASHINGTON, Sept. 4, 2025 /PRNewswire/ -- The Heart Failure Society of America (HFSA) is pleased to announce the Late Breaking Clinical Research that will be presented at its Annual Scientific Meeting (ASM), September 26-29, at the at the Minneapolis Convention Center in Minneapolis, MN....

(NYSE:RMD) New global clinical insights initiative debuts at World Sleep Congress 2025 to help drive innovation in sleep health care New global clinical insights initiative debuts at World Sleep Congress 2025 to help drive innovation in sleep health care

BETHLEHEM, Pa., Sept. 3, 2025 /PRNewswire/ -- In recent months, St. Luke's ambulances equipped with whole blood have saved numerous lives, including car accident survivors and a gunshot victim. Whole blood is a powerful, lifesaving tool because, unlike IV fluid, it contains vital...

COLUMBUS, Ohio--(BUSINESS WIRE)--The Emily Program, a nationally recognized leader in eating disorder treatment, announced the launch of nasogastric (NG) tube services at its Columbus residential site to broaden recovery options and better serve local patients. NG tube care involves inserting a flexible tube through the nose and into the stomach and enables medically supervised nutritional support for patients who are unable to meet their dietary needs through oral intake alone. This approach a

(NASDAQ:MGLN) Team-based approach fosters clinical partnerships and provides tools to support physicians who treat children with mild to moderate behavioral health conditions FRISCO, Texas, Sept. 3, 2025 /PRNewswire/ -- Magellan Health, Inc., a clinical-first leader in behavioral health and related...

This report provides an evidence-based review of current treatments for managing dry eye disease (DED) and highlights support for TearCare based on strong clinical data This report provides an evidence-based review of current treatments for managing dry eye disease (DED) and highlights support for TearCare based on strong clinical data

Recognition reflects Wonderfeel's commitment to real-world science and everyday outcomes SAN FRANCISCO, Sept. 2, 2025 /PRNewswire/ -- Wonderfeel Biosciences, a frontrunner in wellness biosciences, has achieved two milestone-marking moments in its mission to bring longevity science to...

Powered by proprietary single-molecule next-generation sequencing (smNGS) technology, Northstar Select sets a new standard in sensitivity for non-invasive, blood-based comprehensive genomic profiling of advanced solid tumor cancers by uncovering over 50% more clinically actionable...

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to rinatabart sesutecan (Rina-S®), an investigational folate receptor alpha (FRα)-directed, TOPO1-inhibitor antibody-drug conjugate (ADC), for the treatment of adult patients with recurrent or progressive endometrial cancer (EC) who have disease progression on or following prior treatment with a platinum-containing re

LIXTE Biotechnology (Nasdaq: LIXT) advancing its clinical strategy by focusing on high-need, high-value cancer indications that currently offer limited tre

Propanc is entering a transformational stage as it prepares for the advancement of its lead asset, “PRP”, to enter a Phase 1B, First-In-Human (FIH) study

In this free webinar, learn how streamlined workflows and intuitive interfaces help pathologists reduce time spent on slide review and data capture — freeing up hours for deeper analysis. Attendees will see how built-in checks, standardized terminology and smart glossaries reduce errors...

CNSide® can quantify leptomeningeal metastases (LM) over time and monitor changes in the expression of multiple targetable mutations

SHANGHAI, Aug. 13, 2025 /PRNewswire/ -- Smartee Denti-Technology announces the publication of a case report on the application of the S8-SGTB clear aligner therapy for treating adult Class II malocclusion in the Journal of Aligner Orthodontics (JAO). The report, titled "Treatment of Class...

- Duchenne (SGT-003): 15 participants dosed in the Phase 1/2 INSPIRE DUCHENNE trial and dosing remains ongoing; On track to discuss regulatory pathways with U.S. FDA in Q4 2025 -

– Positive ENLIGHTEN 2 Phase 3 results announced in June 2025 propel business activities in manufacturing, regulatory strategy and ENLIGHTEN clinical dataset analysis to advance path forward for LYR-210 for treatment of chronic rhinosinusitis (CRS) –

- Cognition and FDA align on enriched population, study design, and endpoints -

PHOENIX--(BUSINESS WIRE)--Digital health startup, Drive Health, launches its Clinical Advisory Council and is now accepting applications